Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J Clin. 2021;71(1):7–33.
Park W, Chawla A, O’Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326(9):851–62.
CAS PubMed Article Google Scholar
Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, et al. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 2015;6(1):9.
PubMed PubMed Central Article Google Scholar
Nagaraju GP, Malla RR, Basha R, Motofei IG. Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1. Semin Cancer Biol. 2021; S1044–579X(21)00270–4.
Uhlitz F, Zamarin D. Rejuvenating dysfunctional T cells in ovarian cancer: CD28 is the license to kill. Cancer Cell. 2021;S1535–6108(21):00562–6.
Zhang B, Vogelzang A, Miyajima M, Sugiura Y, Wu Y, Chamoto K, et al. B cell-derived GABA elicits IL-10+ macrophages to limit anti-tumour immunity. Nature. 2021;599(7885):471–6.
CAS PubMed PubMed Central Article Google Scholar
Au L, Hatipoglu E, Robert de Massy M, Litchfield K, Beattie G, Rowan A, et al. TRACERx Renal Consortium. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell. 2021;39(11):1497–518.
CAS PubMed PubMed Central Article Google Scholar
Nguyen NT, Huang K, Zeng H, Jing J, Wang R, Fang S, et al. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat Nanotechnol. 2021;16(12):1424–34.
CAS PubMed PubMed Central Article Google Scholar
Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2021;76(2):353–63.
PubMed Article CAS Google Scholar
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5.
CAS PubMed PubMed Central Article Google Scholar
Mazur PK, Siveke JT. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Gut. 2012;61(10):1488–500.
Stromnes IM, Hulbert A, Pierce RH, Greenberg PD, Hingorani SR. T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma. Cancer Immunol Res. 2017;5(11):978–91.
CAS PubMed PubMed Central Article Google Scholar
Jiang ZB, Huang JM, Xie YJ, Zhang YZ, Chang C, Lai HL, et al. Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis. J Exp Clin Cancer Res. 2020;39(1):249.
CAS PubMed PubMed Central Article Google Scholar
Schmit K, Michiels C. TMEM proteins in cancer: a review. Front Pharmacol. 2018;9:1345.
CAS PubMed PubMed Central Article Google Scholar
Koteluk O, Bielicka A, Lemańska Ż, Jóźwiak K, Klawiter W, Mackiewicz A, et al. The landscape of transmembrane protein family members in head and neck cancers: their biological role and diagnostic utility. Cancers (Basel). 2021;13(19):4737.
Carroll J, He J, Ding S, Fearnley IM, Walker JE. TMEM70 and TMEM242 help to assemble the rotor ring of human ATP synthase and interact with assembly factors for complex I. Proc Natl Acad Sci U S A. 2021;118(13):e2100558118.
CAS PubMed PubMed Central Article Google Scholar
Luo S, Wang X, Bai M, Jiang W, Zhang Z, Chen Y, et al. The conserved autoimmune-disease risk gene TMEM39A regulates lysosome dynamics. Proc Natl Acad Sci U S A. 2021;118(6):e2011379118.
CAS PubMed PubMed Central Article Google Scholar
Duan J, Qian Y, Fu X, Chen M, Liu K, Liu H, et al. TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma. Aging (Albany NY). 2021;13(4):5585–606.
Rao J, Wu X, Zhou X, Deng R, Ma Y. TMEM205 is an independent prognostic factor and is associated with immune cell infiltrates in hepatocellular carcinoma. Front Genet. 2020;11:575776.
CAS PubMed PubMed Central Article Google Scholar
Listing H, Mardin WA, Wohlfromm S, Mees ST, Haier J. MiR-23a/-24-induced gene silencing results in mesothelial cell integration of pancreatic cancer. Br J Cancer. 2015;112(1):131–9.
CAS PubMed Article Google Scholar
Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7.
CAS PubMed PubMed Central Article Google Scholar
Zhang S, Zang D, Cheng Y, Li Z, Yang B, Guo T. Identification of key gene and pathways for the prediction of peritoneal metastasis of gastric cancer by co-expression analysis. J Cancer. 2020;11(10):3041–51.
CAS PubMed PubMed Central Article Google Scholar
Hazra A, Gogtay N. Biostatistics series module 3: comparing groups: numerical variables. Indian J Dermatol. 2016;61(3):251–60.
PubMed PubMed Central Article Google Scholar
Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.
CAS PubMed Article Google Scholar
Xu L, Zhang Y, Liu J, Qu J, Hu X, Zhang F, et al. TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells. Eur J Cancer. 2012;48(17):3288–99.
CAS PubMed Article Google Scholar
Zang D, Zhang C, Li C, Fan Y, Li Z, Hou K, et al. LPPR4 promotes peritoneal metastasis via Sp1/integrin α/FAK signaling in gastric cancer. Am J Cancer Res. 2020;10(3):1026–44.
CAS PubMed PubMed Central Google Scholar
Marcq E, Audenaerde JRV, Waele J, Jacobs J, Loenhout JV, Cavents G, et al. Building a bridge between chemotherapy and immunotherapy in malignant pleural mesothelioma: investigating the effect of chemotherapy on immune checkpoint expression. Int J Mol Sci. 2019;20(17):4182.
PubMed Central Article CAS Google Scholar
Marcq E, Van Audenaerde JRM, De Waele J, Merlin C, Pauwels P, van Meerbeeck JP, et al. The search for an interesting partner to combine with PD-L1 blockade in mesothelioma: focus on Tim-3 and LAG-3. Cancers. 2021;13(2):282.
CAS PubMed PubMed Central Article Google Scholar
Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. CELL RES. 2017;27(1):109–18.
CAS PubMed Article Google Scholar
Jairath NK, Farha MW, Jairath R, Harms PW, Tsoi LC, Tejasvi T. Prognostic value of intratumoral lymphocyte-to-monocyte ratio and M0 macrophage enrichment in tumor immune microenvironment of melanoma. Melanoma Manag. 2020; 7(4):Mmt51.
Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44.
CAS PubMed PubMed Central Article Google Scholar
Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–40.
PubMed PubMed Central Article Google Scholar
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–99.
PubMed PubMed Central Article CAS Google Scholar
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, NY). 2015;348(6230):124–8.
CAS PubMed Central Article Google Scholar
Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56.
CAS PubMed PubMed Central Article Google Scholar
Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.
Dreyer SB, Chang DK, Bailey P, Biankin AV. Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clin Cancer Res. 2017;23(7):1638–46.
Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA J. 2016;7(1):23.
PubMed PubMed Central Article Google Scholar
Foley K, Kim V, Jaffee E, Zheng L. Current progress in immunotherapy for pancreatic cancer. Cancer Lett. 2016;381(1):244–51.
留言 (0)